Search results for "treatment targets"

showing 7 items of 7 documents

Multi-omics approaches to improve malaria therapy.

2021

Malaria contributes to the most widespread infectious diseases worldwide. Even though current drugs are commercially available, the ever-increasing drug resistance problem by malaria parasites poses new challenges in malaria therapy. Hence, searching for efficient therapeutic strategies is of high priority in malaria control. In recent years, multi-omics technologies have been extensively applied to provide a more holistic view of functional principles and dynamics of biological mechanisms. We briefly review multi-omics technologies and focus on recent malaria progress conducted with the help of various omics methods. Then, we present up-to-date advances for multi-omics approaches in malari…

0301 basic medicineProteomicsPlasmodiumComputer scienceDrug ResistanceDisease03 medical and health sciencesAntimalarials0302 clinical medicineTreatment targetsBasic researchparasitic diseasesmedicineAnimalsHumansMetabolomicsPharmacologyGenomicsmedicine.diseaseMalaria030104 developmental biologyRisk analysis (engineering)Drug development030220 oncology & carcinogenesisMulti omicsMalaria controlMalariaPharmacological research
researchProduct

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications

2021

Preclinical studies provided some important insights into the action of glucagon-like peptide 1 (GLP-1) in taste perception. This review examines the literature to uncover some molecular mechanisms and connections between GLP-1 and the gustatory coding. Local GLP-1 production in the taste bud cells, the expression of GLP-1 receptor on the adjacent nerves, a functional continuum in the perception of sweet chemicals from the gut to the tongue and an identification of GLP-1 induced signaling pathways in peripheral and central gustatory coding all strongly suggest that GLP-1 is involved in the taste perception, especially sweet. However, the impact of GLP-1 based therapies on gustatory coding i…

0301 basic medicineTasteendocrine systemobesitymedia_common.quotation_subject030209 endocrinology & metabolismReviewBiologyCatalysisGlucagon-Like Peptide-1 Receptorlcsh:ChemistryInorganic Chemistrytaste03 medical and health sciences0302 clinical medicineTreatment targetsTonguetongueGlucagon-Like Peptide 1PerceptionmedicineAnimalsHumansGLP-1 Sweet Taste Tongue Animals Glucagon-Like Peptide-1 Receptor Humans Obesity Signal Transduction Taste Taste Buds Taste PerceptionPhysical and Theoretical ChemistryReceptorTaste Bud Cellslcsh:QH301-705.5Molecular BiologySpectroscopymedia_commonOrganic Chemistrydigestive oral and skin physiologyTaste PerceptionGeneral MedicineTaste BudsGlucagon-like peptide-1Computer Science Applications030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Signal transductionGLP-1Neurosciencesweethormones hormone substitutes and hormone antagonistsSignal TransductionInternational Journal of Molecular Sciences
researchProduct

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment

2016

Abstract: An in silico pathway analysis was performed in order to improve current knowledge on the molecular drivers of cervical cancer and detect potential targets for treatment. Three publicly available Affymetrix gene expression data-sets (GSE5787, GSE7803, GSE9750) were retrieved, vouching for a total of 9 cervical cancer cell lines (CCCLs), 39 normal cervical samples, 7 CIN3 samples and 111 cervical cancer samples (CCSs). Predication analysis of microarrays was performed in the Affymetrix sets to identify cervical cancer biomarkers. To select cancer cell-specific genes the CCSs were compared to the CCCLs. Validated genes were submitted to a gene set enrichment analysis (GSEA) and Expre…

0301 basic medicineUterine Cervical NeoplasmMAPK3Uterine Cervical NeoplasmsBioinformaticsHeLa CellMitogen-Activated Protein Kinase0302 clinical medicineTransforming Growth Factor betaMedicineOligonucleotide Array Sequence AnalysisCancerCervical cancerABLCell CycleIn silico pathway analysiCell cycleGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisFemaleDNA microarrayMitogen-Activated Protein KinasesTreatment targetResearch PaperHumanin silico pathway analysisMAP Kinase Signaling SystemIn silicoComputational biologytreatment targetsProto-Oncogene Proteins c-myc03 medical and health sciencesCell Line TumorBiomarkers TumorHumansComputer SimulationAmino Acid SequenceBiologyCervical carcinomabusiness.industryOligonucleotide Array Sequence AnalysiGene Expression ProfilingCancerComputational Biologymedicine.diseaseChromatin Assembly and DisassemblyGene expression profiling030104 developmental biologyHuman medicinebusinessHeLa CellsOncotarget
researchProduct

Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder

2012

AbstractBackgroundTo analyse insight of illness during the course of inpatient treatment, and to identify influencing factors and predictors of insight.MethodsInsight into illness was examined in 399 patients using the item G12 of the Positive and Negative Syndrome Scale (“lack of insight and judgement”). Ratings of the PANSS, HAMD, UKU, GAF, SOFAS, SWN-K and Kemp's compliance scale were performed and examined regarding their potential association with insight. The item G12 was kept as an ordinal variable to compare insight between subgroups of patients.ResultsAlmost 70% of patients had deficits in their insight into illness at admission. A significant improvement of impairments of insight …

AdultMaleOrdinal datamedicine.medical_specialtyMedizin03 medical and health sciences0302 clinical medicineTreatment targetsPredictive Value of TestsHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleAwarenessmedicine.disease030227 psychiatryPsychiatry and Mental healthInsight into illnessSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumEuropean Psychiatry
researchProduct

Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

2019

Abstract Aims In 2017 the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) revised the criteria for access to therapy for patients with chronic hepatitis C as part of a three-year plan to eradicate HCV. We conducted a Delphi study to determine strategies to identify and treat patients with HCV and to develop through a shared pathway, a model to manage patient referral and optimize prescription center capacity with the overall aim of increasing access to therapy. Methods The process took place in two phases – Phase I (January 2017), before the criteria for treatment of HCV were revised and Phase II (May 2017) when AIFA developed a framework for the eradication of HCV infection in Ita…

AdultMalemedicine.medical_specialtyDelphi TechniqueGeneral PracticeDelphi methodDelphi methodAntiviral AgentsDrug PrescriptionsHealth Services AccessibilityMedication AdherencemodelsPatient referralTreatment targetsChronic hepatitismedicineHumansdelphi method; direct-acting antivirals; disease eradication; hepatitis c virus; adult; aged; antiviral agents; disease eradication; drug prescriptions; female; general practice; health care surveys; health services accessibility; hepatitis c chronic; humans; italy; male; medication adherence; middle aged; models theoretical; quality Improvement; referral and consultation; delphi techniquehepatitis cMedical prescriptiontheoreticalReferral and Consultationdirect-acting antiviralsAgedHepatitisdirect-acting antiviralHepatologyDisease Eradicationbusiness.industryHepatitis C virusGastroenterologyDrug agencyHepatitis C ChronicMiddle AgedModels Theoreticalmedicine.diseaseQuality ImprovementchronicItalyHealth Care SurveysFamily medicineFemaledisease eradicationbusiness
researchProduct

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

2012

Abstract Background Chondrosarcoma is the second most common primary sarcoma of bone. High-grade conventional chondrosarcoma and dedifferentiated chondrosarcoma have a poor outcome. In pre-clinical research aiming at the identification of novel treatment targets, the need for representative cell lines and model systems is high, but availability is scarce. Methods We developed and characterized three cell lines, derived from conventional grade III chondrosarcoma (L835), and dedifferentiated chondrosarcoma (L2975 and L3252) of bone. Proliferation and migration were studied and we used COBRA-FISH and array-CGH for karyotyping and genotyping. Immunohistochemistry for p16 and p53 was performed a…

MaleBone neoplasmCancer ResearchPathologymedicine.medical_specialtyIDH1Transplantation HeterologousChondrosarcomaMice NudeBone Neoplasmsp16Bone neoplasmlcsh:RC254-282MiceTreatment targetsCell MovementCell Line TumorGeneticsmedicineAnimalsHumansDedifferentiated chondrosarcomaIn Situ Hybridization FluorescenceComparative Genomic HybridizationNeoplasm Gradingbusiness.industryConventional ChondrosarcomaMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRadiographyRadiusOncologyMutationIDH1IDH2Neoplasm GradingChondrosarcomaCell linebusinessPrimary sarcomaResearch ArticleBMC Cancer
researchProduct

INFLAMMATION IN IRRITABLE BOWEL SYNDROME: MYTH OR NEW TREATMENT TARGET?

2016

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms u…

Pathologymedicine.medical_specialtyMEDLINEAnti-Inflammatory AgentsInflammationCochrane LibraryBioinformaticsMast cell03 medical and health sciences0302 clinical medicineTreatment targetsGastrointestinal AgentsIntestinal inflammationmedicinePathologyAnimalsHumansMolecular Targeted TherapyTopic HighlightIntestinal MucosaIrritable bowel syndromeInflammationSettore MED/12 - GastroenterologiaMechanism (biology)business.industrySettore BIO/16 - Anatomia UmanaGastroenterologyGeneral MedicineInflammation; Irritable bowel syndrome; Mast cells; Neuroendocrine cells; Pathologymedicine.diseaseEnteritisClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia Generale030220 oncology & carcinogenesisNeuroendocrine cell030211 gastroenterology & hepatologymedicine.symptomInflammation Mediatorsbusiness
researchProduct